WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
Status:
RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This prospective Phase II study aims to evaluate the preliminary efficacy and safety of WAST cells combined with docetaxel as second-line therapy in patients with advanced NSCLC resistant to PD-1 inhibitors.
Phase:
PHASE2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital